167 related articles for article (PubMed ID: 2831187)
21. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.
Georgiadou D; Chroni A; Vezeridis A; Zannis VI; Stratikos E
PLoS One; 2011; 6(11):e27037. PubMed ID: 22069485
[TBL] [Abstract][Full Text] [Related]
22. Structure-guided protein engineering modulates helix bundle exchangeable apolipoprotein properties.
Kiss RS; Weers PM; Narayanaswami V; Cohen J; Kay CM; Ryan RO
J Biol Chem; 2003 Jun; 278(24):21952-9. PubMed ID: 12684504
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.
Rall SC; Weisgraber KH; Innerarity TL; Mahley RW
Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4696-700. PubMed ID: 6289314
[TBL] [Abstract][Full Text] [Related]
24. A two-module region of the low-density lipoprotein receptor sufficient for formation of complexes with apolipoprotein E ligands.
Fisher C; Abdul-Aziz D; Blacklow SC
Biochemistry; 2004 Feb; 43(4):1037-44. PubMed ID: 14744149
[TBL] [Abstract][Full Text] [Related]
25. Single-step purification of two functional human apolipoprotein E variants hyperexpressed in Escherichia coli.
Pillot T; Barbier A; Visvikis A; Lozac'h K; Rosseneu M; Vandekerckhove J; Siest G
Protein Expr Purif; 1996 Jun; 7(4):407-14. PubMed ID: 8776760
[TBL] [Abstract][Full Text] [Related]
26. Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase.
Liu H; Talmud PJ; Lins L; Brasseur R; Olivecrona G; Peelman F; Vandekerckhove J; Rosseneu M; Labeur C
Biochemistry; 2000 Aug; 39(31):9201-12. PubMed ID: 10924113
[TBL] [Abstract][Full Text] [Related]
27. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
28. Helix orientation of the functional domains in apolipoprotein e in discoidal high density lipoprotein particles.
Narayanaswami V; Maiorano JN; Dhanasekaran P; Ryan RO; Phillips MC; Lund-Katz S; Davidson WS
J Biol Chem; 2004 Apr; 279(14):14273-9. PubMed ID: 14739281
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
Marais AD
Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
[TBL] [Abstract][Full Text] [Related]
30. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.
Innerarity TL; Friedlander EJ; Rall SC; Weisgraber KH; Mahley RW
J Biol Chem; 1983 Oct; 258(20):12341-7. PubMed ID: 6313652
[TBL] [Abstract][Full Text] [Related]
31. Replacement of helix 1' enhances the lipid binding activity of apoE3 N-terminal domain.
Redmond KA; Murphy C; Narayanaswami V; Kiss RS; Hauser P; Guigard E; Kay CM; Ryan RO
FEBS J; 2006 Feb; 273(3):558-67. PubMed ID: 16420479
[TBL] [Abstract][Full Text] [Related]
32. Pyrene fluorescence analysis offers new insights into the conformation of the lipoprotein-binding domain of human apolipoprotein E.
Patel AB; Khumsupan P; Narayanaswami V
Biochemistry; 2010 Mar; 49(8):1766-75. PubMed ID: 20073510
[TBL] [Abstract][Full Text] [Related]
33. A monomeric human apolipoprotein E carboxyl-terminal domain.
Fan D; Li Q; Korando L; Jerome WG; Wang J
Biochemistry; 2004 May; 43(17):5055-64. PubMed ID: 15109264
[TBL] [Abstract][Full Text] [Related]
34. Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of ApoE suffices for receptor binding.
Li X; Kan HY; Lavrentiadou S; Krieger M; Zannis V
J Biol Chem; 2002 Jun; 277(24):21149-57. PubMed ID: 11861652
[TBL] [Abstract][Full Text] [Related]
35. Differences in the binding capacity of human apolipoprotein E3 and E4 to size-fractionated lipid emulsions.
Perugini MA; Schuck P; Howlett GJ
Eur J Biochem; 2002 Dec; 269(23):5939-49. PubMed ID: 12444983
[TBL] [Abstract][Full Text] [Related]
36. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
Boren J; Lee I; Zhu W; Arnold K; Taylor S; Innerarity TL
J Clin Invest; 1998 Mar; 101(5):1084-93. PubMed ID: 9486979
[TBL] [Abstract][Full Text] [Related]
37. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins.
Dong LM; Weisgraber KH
J Biol Chem; 1996 Aug; 271(32):19053-7. PubMed ID: 8702576
[TBL] [Abstract][Full Text] [Related]
38. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E.
Hui DY; Innerarity TL; Mahley RW
J Biol Chem; 1984 Jan; 259(2):860-9. PubMed ID: 6319389
[TBL] [Abstract][Full Text] [Related]
39. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice.
van Vlijmen BJ; van Dijk KW; van't Hof HB; van Gorp PJ; van der Zee A; van der Boom H; Breuer ML; Hofker MH; Havekes LM
J Biol Chem; 1996 Nov; 271(48):30595-602. PubMed ID: 8940032
[TBL] [Abstract][Full Text] [Related]
40. Inter-molecular coiled-coil formation in human apolipoprotein E C-terminal domain.
Choy N; Raussens V; Narayanaswami V
J Mol Biol; 2003 Nov; 334(3):527-39. PubMed ID: 14623192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
